EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports

Shea-Lee Godin iD, Tyler Kingma, Ashwin Pillai iD, Obada Kholoki iD, Agnes S Kim iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70675 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Reports, 2026. Verfasst von Shea-Lee Godin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Connecticut Health, Farmington, Connecticut, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Myocarditis, Neoplasms, Pericarditis. Die Arbeit nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reports of immune checkpoint inhibitor (ICI) therapy‐associated immune‐related adverse events (irAEs) exhibit considerable heterogeneity, particularly when comparing data from clinical trials and real‐world observational studies.

Methods

We conducted a systematic review of real‐world observational studies (case reports and series) reporting cardiovascular irAEs in PubMed and Embase from inception to April 1, 2024. We analyzed 116 case reports from 115 studies and highlighted the commonest irAEs, treatments instituted, and ensuing outcomes.

Results

Myocarditis was the most common, accompanied frequently by pericarditis and heart failure. Treatment typically included corticosteroids and discontinuation of ICI therapy. Higher doses of corticosteroids appeared promising. Refractory cases benefited from plasmapheresis, intravenous immunoglobulin, mycophenolate, tacrolimus, or infliximab. Rechallenging ICI therapy after irAEs resulted in mixed outcomes.

Conclusions

Given the heterogeneity of data, analysis of aggregated data from central repositories like Side Effect Registry Immuno‐Oncology (SERIO) would be invaluable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsMyocarditisNeoplasmsPericarditisHeart FailureHumansCase Reports as Topic

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of Connecticut Health, Farmington, Connecticut, USA.
  • Department of Medicine, Division of Cardiology, University of Connecticut Health, Farmington, Connecticut, USA.

ORCID-Profile: Shea-Lee Godin, Ashwin Pillai, Obada Kholoki, Agnes S Kim

Zitieren

APA

Godin, S. L., Kingma, T., Pillai, A., Kholoki, O., & Kim, A. S. (2026). Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports. Cancer Reports. https://doi.org/10.1002/cnr2.70675

Vancouver

Godin SL, Kingma T, Pillai A, Kholoki O, Kim AS. Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports. Cancer Reports. 2026. doi:10.1002/cnr2.70675

BibTeX
@article{Godin2026,
  author = {Godin, Shea-Lee and Kingma, Tyler and Pillai, Ashwin and Kholoki, Obada and Kim, Agnes S},
  title = {Cardiovascular Immune‐Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Summary of Case Reports},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70675}
}
Kostenlos starten →